Brian Conner
Keine laufenden Positionen mehr
Profil
Brian Conner worked as a Vice President & Head-Compliance at Strongbridge Biopharma Plc.
Prior to that, he worked as a Director at Huron Consulting Group, Inc. and as an Assistant Compliance Officer at Shire Pharmaceuticals, Inc. He completed his undergraduate degree from Drexel University.
Ehemalige bekannte Positionen von Brian Conner
| Unternehmen | Position | Ende |
|---|---|---|
| HURON CONSULTING GROUP INC. | Director/Board Member | 01.06.2017 |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | 01.01.2015 |
| STRONGBRIDGE BIOPHARMA | Compliance Officer | - |
Ausbildung von Brian Conner
| Drexel University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HURON CONSULTING GROUP INC. | Commercial Services |
| Private Unternehmen | 2 |
|---|---|
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Strongbridge Biopharma Plc
 Strongbridge Biopharma Plc Pharmaceuticals: MajorHealth Technology Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA. | Health Technology |
